208 related articles for article (PubMed ID: 32885893)
21. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
22. Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines.
Zhang Z; Golomb L; Meyerson M
Cancer Res; 2022 Jun; 82(11):2171-2184. PubMed ID: 35395071
[TBL] [Abstract][Full Text] [Related]
23. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
24. Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples.
Mizuarai S; Machida T; Kobayashi T; Komatani H; Itadani H; Kotani H
Mol Cancer; 2011 Mar; 10():31. PubMed ID: 21447152
[TBL] [Abstract][Full Text] [Related]
25. The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors.
Louis-Brennetot C; Coindre JM; Ferreira C; Pérot G; Terrier P; Aurias A
Genes Chromosomes Cancer; 2011 Nov; 50(11):896-907. PubMed ID: 21910158
[TBL] [Abstract][Full Text] [Related]
26. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
[TBL] [Abstract][Full Text] [Related]
27. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
[TBL] [Abstract][Full Text] [Related]
28. Mutation analysis of the pRb pathway in 2',3'-dideoxycytidine- and 1, 3-butadiene-induced mouse lymphomas.
Zhuang SM; Wiseman RW; Söderkvist P
Cancer Lett; 2000 May; 152(2):129-34. PubMed ID: 10773403
[TBL] [Abstract][Full Text] [Related]
29. Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma.
Iolascon A; Giordani L; Moretti A; Basso G; Borriello A; Della Ragione F
Hepatology; 1998 Apr; 27(4):989-95. PubMed ID: 9537438
[TBL] [Abstract][Full Text] [Related]
30. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
[No Abstract] [Full Text] [Related]
31. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
32. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
33. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
34. An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma.
Wang Q; Bai J; Abliz A; Liu Y; Gong K; Li J; Shi W; Pan Y; Liu F; Lai S; Yang H; Lu C; Zhang L; Chen W; Xu R; Cai H; Ke Y; Zeng C
Genomics Proteomics Bioinformatics; 2015 Aug; 13(4):258-70. PubMed ID: 26386145
[TBL] [Abstract][Full Text] [Related]
35. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
36. Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors.
Schmidt BA; Rose A; Steinhoff C; Strohmeyer T; Hartmann M; Ackermann R
Cancer Res; 2001 May; 61(10):4214-21. PubMed ID: 11358847
[TBL] [Abstract][Full Text] [Related]
37. Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy.
Necchi A; Bratslavsky G; Corona RJ; Chung JH; Millis SZ; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Severson E; Daniel S; Killian JK; Ali SM; Schrock AB; Reddy P; Miller VA; Welsh A; Gay LM; Ross JS
Eur Urol Focus; 2020 Jan; 6(1):122-130. PubMed ID: 30025711
[TBL] [Abstract][Full Text] [Related]
38. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers.
Noel EE; Yeste-Velasco M; Mao X; Perry J; Kudahetti SC; Li NF; Sharp S; Chaplin T; Xue L; McIntyre A; Shan L; Powles T; Oliver RT; Young BD; Shipley J; Berney DM; Joel SP; Lu YJ
Am J Pathol; 2010 Jun; 176(6):2607-15. PubMed ID: 20395447
[TBL] [Abstract][Full Text] [Related]
39. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
